SNS-314 is a potent and selective inhibitor of Aurora B kinase, an enzyme involved in cell division and mitotic regulation. It has been primarily investigated for its potential in cancer therapy due to its ability to disrupt proper chromosome alignment and cytokinesis, leading to polyploidy and apoptosis in rapidly dividing tumor cells. The compound shows activity against various solid tumors and hematological malignancies in preclinical models. Its selectivity for Aurora B over Aurora A helps reduce off-target effects, making it a valuable tool in oncology research. SNS-314 is used in laboratory studies to probe mitotic mechanisms and evaluate the therapeutic impact of Aurora kinase inhibition. While not currently approved for clinical use, it serves as a lead compound for the development of novel antimitotic drugs.